Expertise in
17
conditions

Dr. Davendra P. Sohal

Oncology
Trustees Of The University Of Pennsylvania
3400 Spruce St, 
Philadelphia, PA 
Accepting New Patients
Expertise in
17
conditions
Trustees Of The University Of Pennsylvania
3400 Spruce St, 
Philadelphia, PA 

Overview

Davendra Sohal is an Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Sohal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 95 peer reviewed articles and participating in 13 clinical trials. Dr. Sohal is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in OH

Hospital Affiliations

West Chester Hospital
University Of Cincinnati Medical Center, LLC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Trustees of the University of Pennsylvania
3400 Spruce St, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Nivolumab, Paclitaxel
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
An Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma: A Phase II Trial
An Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma: A Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Folfirinox, Gemcitabine
Study Phase: Phase 2
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Enrollment Status: Terminated
Publish Date: May 06, 2026
Intervention Type: Drug, Procedure
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy
A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy
Enrollment Status: Suspended
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drugs: ABTL0812, Gemcitabine and Nab-Paclitaxel
Study Phase: Phase 1/Phase 2
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase II Study of Second-Line Therapy With Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
A Phase II Study of Second-Line Therapy With Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: October 23, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

95 Total Publications

ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma.
ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma.
Journal: Annals of surgical oncology
Published: June 25, 2026
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (0.2 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (0.2 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arati Desai is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Desai is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Desai is board certified in Medical Oncology, 2008, Hospice And Palliative Medicine, 2012, and Internal Medicine, 2004. Dr. Desai is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request

Penn Mesothelioma And Pleural Program

51 N. 39th Street, Pavilion For Advanced Care, First Floor, 
Philadelphia, PA 
 (0.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Corey Langer is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Langer is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Langer is board certified in Hematology, 1986, Medical Oncology, 1987, and Internal Medicine, 1984. Dr. Langer is currently accepting new patients.

Frequently Asked Questions about Dr. Davendra P. Sohal

How do I make an appointment with Dr. Davendra P. Sohal?

You can book an appointment with Dr. Davendra P. Sohal by calling their office at 216-444-8258. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Davendra P. Sohal a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Davendra P. Sohal is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Davendra P. Sohal specialize in?

While Dr. Davendra P. Sohal is a Oncology, they have specific expertise in Pancreatic Cancer, Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Davendra P. Sohal participate in research or clinical trials?

Yes. Dr. Davendra P. Sohal has published 95 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Davendra P. Sohal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Davendra P. Sohal accept my insurance?

Dr. Davendra P. Sohal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 216-444-8258 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sohal's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile